
Sign up to save your podcasts
Or


This episode of SurgOnc Today®, features guest faculty, Astrid Botty Van Den Bruele, MD, and Meghan Flanagan, MD, MPH. In a contemporary group of patients diagnosed with contralateral axillary metastases (CAM), those selected for treatment with presumed curative intent experienced improved OS when compared to stage IV (M1) patients. The current literature, as well as some forthcoming data, adds additional support for re-evaluating the stage IV designation, in favor of N3, and consideration of curative intent treatment in this disease entity.
By Society of Surgical Oncology5
1111 ratings
This episode of SurgOnc Today®, features guest faculty, Astrid Botty Van Den Bruele, MD, and Meghan Flanagan, MD, MPH. In a contemporary group of patients diagnosed with contralateral axillary metastases (CAM), those selected for treatment with presumed curative intent experienced improved OS when compared to stage IV (M1) patients. The current literature, as well as some forthcoming data, adds additional support for re-evaluating the stage IV designation, in favor of N3, and consideration of curative intent treatment in this disease entity.

32,129 Listeners

30,646 Listeners

320 Listeners

495 Listeners

1,315 Listeners

87,299 Listeners

2,440 Listeners

112,539 Listeners

24,677 Listeners

56,431 Listeners

9,194 Listeners

14,397 Listeners

9 Listeners

6,374 Listeners

4,550 Listeners